Annovis Bio(DE:07X)
€0.79+-0.02 (+10.15%)
DE:07X
Annovis Bio financials statements
€0.79
At close:+-0.02 (+10.15%)
Annovis Bio (07X) Ratios
4 Followers
Annovis Bio Ratios
DE:07X's free cash flow for Q2 2026 was $-21.91M. For the 2026 fiscal year, DE:07X's free cash flow was increased by $0.00 and operating cash flow was $-21.91M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Mar 24 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.80 | 3.59 | 2.39 | 4.68 | 30.54 |
| Quick Ratio | 5.80 | 3.59 | 2.39 | 4.68 | 30.54 |
| Cash Ratio | 5.37 | 2.72 | 1.34 | 3.69 | 30.33 |
| Solvency Ratio | -6.82 | -5.32 | -3.13 | -3.29 | -9.62 |
| Operating Cash Flow Ratio | -7.05 | -5641.50 | -9.34 | -2.25 | -6.06 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 16.85M | $ 9.31M | $ -7.75M | $ 28.32M | $ 44.49M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.25 | 1.50 | -1.32 | 1.27 | 1.03 |
| Debt Service Coverage Ratio | 0.00 | -12.27 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | -14.40 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.15 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.68 | 0.46 | 0.13 | 1.11 | 3.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 97.17% | 92.12% | 124.80% | 99.28% | 99.66% |
| Return on Assets (ROA) | -136.87% | -176.58% | -550.57% | -70.31% | -31.49% |
| Return on Equity (ROE) | -171.23% | -264.20% | 725.13% | -89.43% | -32.56% |
| Return on Capital Employed (ROCE) | -170.21% | -265.76% | -759.55% | -90.07% | -32.67% |
| Return on Invested Capital (ROIC) | -170.21% | -265.76% | -759.55% | -90.07% | -32.67% |
| Return on Tangible Assets | -136.87% | -176.58% | -550.57% | -70.31% | -31.49% |
| Earnings Yield | -40.58% | -40.13% | -33.31% | -23.11% | -10.81% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.25 | -1797.29 | -4.43 | -2.12 | -1.20 |
| Free Cash Flow Per Share | -1.25 | -1797.29 | -4.43 | -2.12 | -1.20 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -36.03% | -35731.44% | -23.69% | -15.79% | -6.81% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.47 | -0.00 | -3.00 | -4.33 | -9.25 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 4.22 | 6.58 | -21.77 | 3.87 | 3.01 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.78 | -0.00 | -4.22 | -6.33 | -14.68 |
| Price-to-Operating Cash Flow Ratio | -2.78 | -0.00 | -4.22 | -6.33 | -14.68 |
| Price-to-Earnings Growth (PEG) Ratio | 0.08 | -0.00 | -0.03 | -0.07 | -0.08 |
| Enterprise Value Multiple | -1.79 | -2.23 | -3.62 | -3.18 | -6.09 |
| Enterprise Value | 51.58M | 50.72M | 162.98M | 81.24M | 88.38M |
| EV to EBITDA | -1.79 | -2.23 | -3.62 | -3.18 | -6.09 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -2.01 | -0.00 | -4.08 | -4.69 | -9.68 |
| EV to Operating Cash Flow | -2.01 | -0.00 | -4.08 | -4.69 | -9.68 |
| Tangible Book Value Per Share | 0.82 | 0.76 | -0.86 | 3.47 | 5.83 |
| Shareholders’ Equity Per Share | 0.82 | 0.76 | -0.86 | 3.47 | 5.83 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.40 | -2.02 | -6.23 | -3.10 | -1.90 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.08 | 1.25 | 0.99 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.89 | 0.89 | 0.71 | 0.68 | 0.63 |
Currency in USD
